Influencing factors of bone marrow suppression in patients with non-small cell lung cancer undergoing chemotherapy
Objective:To analyze influencing factors of bone marrow suppression in patients with non-small cell lung cancer(NSCLC)undergoing chemotherapy.Methods:80 patients with NSCLC undergoing chemotherapy admitted to this hospital from May 2020 to May 2023 were selected as the research objects.The clinical data of these patients were collected.The laboratory indicators were tested.These patients were divided into occurrence group and non-occurrence group according to whether bone marrow suppression occurred.Logistic regression was used to analyze the influencing factors of bone marrow suppression in the patients with NSCLC undergoing chemotherapy.Results:There were 56 cases of bone marrow suppression in the 80 patients with NSCLC undergoing chemotherapy with an incidence of 70.00%(56/80).There were no significant differences in gender,smoking history,combined hypertension,combined diabetes,combined coronary heart disease,pathological type,chemotherapy regimen,cytokeratin 19 fragment antigen 21-1 level and carcinoembryonic antigen level between the two groups(P>0.05).The proportions of the patients with age≥65 years,clinical stage III-IV,maximum tumor diameter≥3 cm,number of chemotherapy cycles>4 cycles,bone metastasis,albumin(ALB)<35.00 g/L,platelet to lymphocyte ratio(PLR)>192.50,neutrophil to lymphocyte ratio(NLR)>4.00 in the occurrence group were higher than those in the non-occurrence group,and the differences were statistically significant(P<0.05).Logistic regression analysis showed that age≥65 years old,clinical stage III-IV,maximum tumor diameter≥3 cm,number of chemotherapy cycles>4 cycles,bone metastasis,ALB>192.50,NLR>4.00 were all risk factors for bone marrow suppression in the patients with NSCLC undergoing chemotherapy(OR>1,P<0.05).Conclusions:Age≥65 years old,clinical stage III-IV,maximum tumor diameter≥3 cm,number of chemotherapy cycles>4 cycles,bone metastasis,ALB>192.50,NLR>4.00 are the risk factors for bone marrow suppression in the patients with NSCLC undergoing chemotherapy.
万方数据
维普
